TABLE 2.
Association between the genetic risk score (GRS) of leukocyte telomere length and the risk of 37 UK Biobank cancers.
| Types of cancer | OR (95%CI) | p | FDR | Case | M/F | Age (years) |
| Leukemia | 1.20 (1.02–1.41) | 0.025 | 0.058 | 147 | 79/68 | 67.99 ± 8.17 |
| Rectal cancer | 1.10 (0.96–1.25) | 0.165 | 0.193 | 231 | 134/97 | 70.64 ± 6.17 |
| Tongue cancer | 1.06 (0.88–1.29) | 0.526 | 0.407 | 102 | 65/37 | 68.89 ± 7.35 |
| Squamous cell carcinoma | 1.04 (0.93–1.15) | 0.514 | 0.401 | 332 | 168/164 | 70.89 ± 6.21 |
| Testicular cancer | 1.02 (0.95–1.11) | 0.549 | 0.417 | 595 | 595/0 | 64.78 ± 8.02 |
| Primary bone cancer | 1.02 (0.81–1.29) | 0.845 | 0.524 | 72 | 44/28 | 67.56 ± 8.02 |
| Non-melanoma skin cancer | 1.02 (0.93–1.12) | 0.648 | 0.458 | 472 | 280/192 | 70.01 ± 6.97 |
| Large bowel cancer/Colorectal cancer | 1.02 (0.93–1.12) | 0.739 | 0.490 | 440 | 260/180 | 71.54 ± 5.80 |
| Rodent ulcer | 1.01 (0.92–1.11) | 0.893 | 0.538 | 437 | 203/234 | 70.50 ± 5.77 |
| Esophageal cancer | 1.01 (0.85–1.19) | 0.946 | 0.552 | 137 | 110/27 | 71.98 ± 6.30 |
| Cervical cancer | 1.01 (0.95–1.06) | 0.857 | 0.527 | 1273 | 0/1,273 | 66.16 ± 7.65 |
| Non-Hodgkin’s lymphoma | 0.99 (0.92–1.08) | 0.945 | 0.552 | 593 | 355/238 | 69.40 ± 7.34 |
| Pre-cancer cells cervix | 0.99 (0.94–1.06) | 0.922 | 0.546 | 1117 | 1/1,116 | 63.99 ± 7.98 |
| Breast cancer | 0.98 (0.96–1.01) | 0.164 | 0.193 | 7330 | 37/7,293 | 70.08 ± 6.48 |
| Colon cancer/sigmoid cancer | 0.97 (0.92–1.04) | 0.399 | 0.342 | 1055 | 631/424 | 72.30 ± 5.68 |
| Uterine/endometrial cancer | 0.95 (0.89–1.02) | 0.176 | 0.200 | 752 | 0/752 | 71.27 ± 5.89 |
| Ovarian cancer | 0.95 (0.87–1.03) | 0.222 | 0.224 | 512 | 0/512 | 69.11 ± 7.33 |
| Brain cancer/primary malignant brain tumor | 0.95 (0.80–1.13) | 0.539 | 0.412 | 128 | 62/66 | 64.77 ± 8.81 |
| Prostate cancer | 0.94 (0.91–0.98) | 0.005 | 0.020 | 2410 | 2,410/0 | 73.96 ± 4.08 |
| Skin cancer | 0.94 (0.88–1.00) | 0.065 | 0.106 | 943 | 478/465 | 71.21 ± 6.38 |
| Basal cell carcinoma | 0.94 (0.90–0.97) | 0.001 | 0.010 | 2916 | 1,206/1,710 | 70.02 ± 6.84 |
| Stomach cancer | 0.94 (0.77–1.14) | 0.516 | 0.402 | 96 | 56/40 | 71.33 ± 6.22 |
| Malignant melanoma | 0.91 (0.88–0.95) | 4.57E-06 | 9.56E-05 | 2526 | 1,031/1,495 | 68.95 ± 7.41 |
| Larynx/throat cancer | 0.91 (0.80–1.04) | 0.161 | 0.191 | 228 | 190/38 | 71.12 ± 6.43 |
| Bladder cancer | 0.91 (0.84–0.98) | 0.010 | 0.030 | 725 | 548/177 | 72.30 ± 5.87 |
| Eye and/or adnexal cancer | 0.90 (0.74–1.11) | 0.325 | 0.297 | 95 | 44/51 | 68.82 ± 7.48 |
| Thyroid cancer | 0.90 (0.80–1.01) | 0.067 | 0.108 | 293 | 52/241 | 67.27 ± 7.63 |
| Small intestine/small bowel cancer | 0.90 (0.76–1.06) | 0.206 | 0.216 | 133 | 77/56 | 72.28 ± 5.55 |
| Hodgkin’s lymphoma/Hodgkin’s disease | 0.89 (0.79–0.99) | 0.033 | 0.069 | 321 | 184/137 | 64.96 ± 8.13 |
| Chronic myeloid leukemia | 0.88 (0.71–1.10) | 0.273 | 0.262 | 81 | 44/37 | 68.35 ± 7.98 |
| Lung cancer | 0.88 (0.74–1.06) | 0.172 | 0.197 | 123 | 82/41 | 72.60 ± 5.70 |
| Kidney/renal cell cancer | 0.86 (0.78–0.95) | 0.003 | 0.017 | 401 | 261/140 | 70.22 ± 6.36 |
| Cancer of lip/mouth/pharynx/oral/cavity | 0.86 (0.68–1.09) | 0.213 | 0.220 | 69 | 43/26 | 70.42 ± 5.98 |
| Sarcoma/fibrosarcoma | 0.84 (0.72–0.98) | 0.028 | 0.063 | 164 | 76/88 | 66.73 ± 7.58 |
| Chronic lymphocytic leukemia | 0.82 (0.71–0.94) | 0.005 | 0.020 | 206 | 131/75 | 71.28 ± 6.28 |
| Lymphoma | 0.80 (0.64–1.01) | 0.057 | 0.098 | 78 | 51/27 | 68.69 ± 8.27 |
| Multiple myeloma | 0.77 (0.63–0.93) | 0.006 | 0.021 | 108 | 62/46 | 70.37 ± 7.08 |
The cancers were sorted by the estimated odds ratios (ORs). CI, confidence internal; p, the original p-value; FDR, false discovery rate; M, male; F, female. In bold are significant (i.e., FDR < 0.05) or suggestive associations (i.e., p < 0.05).